Jason Smith compensation by year
UroGen Pharma Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $126,930 | $429,260 | $440,019 | $456,733 | $475,003 | $492,011 |
| Bonus | $100,000 | $30,000 | $10,000 | $47,984 | $0 | $198,960 |
| Stock awards | $491,500 | $55,175 | $57,900 | $376,300 | $518,100 | $220,200 |
| Option awards | $785,242 | $296,758 | $150,639 | $267,691 | $0 | $0 |
| Non-equity incentive | $92,083 | $182,798 | $198,900 | $275,808 | $203,179 | $197,920 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $19,518 | $64,680 | $68,663 | $83,663 | $79,182 | $89,527 |
| Total | $1,615,274 | $1,058,671 | $926,121 | $1,508,179 | $1,275,464 | $1,198,618 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: UroGen Pharma Ltd. DEF 14A filed April 30, 2026, accession 0001437749-26-014237, and prior-year filings. Open the filing on EDGAR.
How this page was built: the UroGen Pharma Ltd. filed document, accession 0001437749-26-014237. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 11,000 | $257,620 | — |
| PSU | 10,000 | $234,200 | — |
| PSU | 6,667 | $156,141 | — |
| PSU | 3,334 | $78,082 | — |
| Option | 13,334 | — | $10.39 |
Per the Outstanding Equity Awards at Fiscal Year-End table in UroGen Pharma Ltd.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
UroGen Pharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Elizabeth Barrett | President and Chief Executive Officer | $4,310,624 |
| Jason Smith · this page | General Counsel and Chief Compliance Officer | $1,198,618 |
| Mark Schoenberg | Chief Medical Officer | $1,170,640 |
Jason Smith's compensation dossier, UroGen Pharma
You have read Jason Smith's totals and holdings. The dossier adds each equity grant UroGen Pharma disclosed for Jason Smith and UroGen Pharma's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full UroGen Pharma compensation record
free company briefThis page is one person within UroGen Pharma's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the UroGen Pharma proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order UroGen Pharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are UroGen Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order URGN
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.